Vertex lost a legal battle against the federal government on Monday over its proposed fertility support program that would ...

Vaxcyte’s stock price dropped by 50% on Monday after the company reported new Phase 2 data from a study evaluating an ...

Corcept Therapeutics’ oral glucocorticoid receptor antagonist has improved survival outcomes in a late-stage test in patients ...

As­traZeneca has great am­bi­tions for its mid-stage oral cho­les­terol drug, be­liev­ing that it could reach peak sales of ...

FDA biologics chief Peter Marks resigns over vaccine dispute with HHS Secretary RFK Jr., causing biotech stocks to drop.

Phase 2 results on Eli Lilly’s experimental heart disease drug showed it could be dosed far less frequently than competing ...

LifeMine restructures with layoffs; PTC's Translarna is pulled in Europe; Opthea ends AMD trials; Apollomics and LaunXP make ...

A New York City drug developer led by well-known executives and backed by some of the top names in biotech investing is ...

New data unveiled Monday showed that Merck’s Winrevair can significantly cut the risk of death, lung transplantation and ...

Heart gene therapy maker Tenaya Therapeutics is laying off 30% to 40% of its staff by the end of the year, the company’s CEO Faraz Ali told Endpoints News by email.

SV Health Investors, fresh off a $250 million fund for dementia-focused biotechs, has unveiled its latest effort, this time ...

Vertex halts VX-264 diabetes cell therapy due to poor efficacy in Phase 1/2 study, but continues Phase 3 trial of zimislecel ...